Current Problems in Cancer
Volume 31, Issue 3 , Pages 182-201 , May 2007

Racial Differences in the Incidence and Outcomes for Patients with Hematological Malignancies

  • Christopher R. Flowers, MD, MS

      Affiliations

    • Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    • Corresponding Author InformationAddress correspondence to Christopher R. Flowers, MD, MS, Clinical Director, Center for Oncology Informatics, Assistant Professor, Winship Cancer Institute, 1365 Clifton Road, N.E., Building C, Suite 3006, Emory University, Atlanta, GA 30322, USA.
    • ,
  • Roni Glover

      Affiliations

    • School of Social Work, Clark Atlanta University, Atlanta, Georgia, USA
    • ,
  • Sagar Lonial, MD

      Affiliations

    • Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA
    • ,
  • Otis W. Brawley, MD

      Affiliations

    • Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia, USA

References 

  1. American Cancer Society. Cancer Facts & Figures 2006. Available from: http://www.cancer.org/docroot/stt/stt0.asp. Accessed Feb. 27, 2006.
  2. Cancer Stat Fact Sheets. Available from: http://seer.cancer.gov/statfacts/html/nhl.html?statfactspage=nhl.html&x=13&y=14. Accessed March 12, 2006.
  3. Freeman HP. Commentary on the meaning of race in science and society. Cancer Epidemiol Biomarkers Prev. 2003;12(3):232s–236s
  4. Brawley OW. Lung cancer and race: equal treatment yields equal outcome among equal patients, but there is no equal treatment. J Clin Oncol. 2006;24(3):332–333
  5. American Cancer Society. Cancer Facts and Figures for African Americans 2005-2006. Available from: http://www.cancer.org/docroot/stt/stt0.asp. Accessed April 12, 2006.
  6. Bach PB, Schrag D, Brawley OW, Galaznik A, Yakren S, Begg CB. Survival of blacks and whites after a cancer diagnosis. Jama Apr 24. 2002;287(16):2106–2113
  7. Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. J Natl Cancer Inst. 2002;94(5):334–357
  8. Bradley CJ, Given CW, Roberts C. Disparities in cancer diagnosis and survival. Cancer. 2001;91(1):178–188
  9. Brawley OW. Introduction: cancer and health disparities. Cancer Metastasis Rev. 2003;22(1):7–9
  10. Ghafoor A, Jemal A, Cokkinides V, et al. Cancer statistics for African Americans. CA Cancer J Clin. 2002;52(6):326–341
  11. Cancer Stat Fact Sheets: Leukemia. Available from: http://seer.cancer.gov/statfacts/html/nhl.html?statfactspage=nhl.html&x=13&y=14. Accessed March 12, 2006.
  12. Gilliland DG. Molecular genetics of human leukemia. Leukemia. 1998;12(suppl 1):S7–S12
  13. Bhatia S, Robison LL. Epidemiology of leukemia and lymphoma. Curr Opin Hematol. 1999;6(4):201–204
  14. Mitchell JM, Meehan KR, Kong J, Schulman KA. Access to bone marrow transplantation for leukemia and lymphoma: the role of sociodemographic factors. J Clin Oncol. 1997;15(7):2644–2651
  15. Weston B, Grufferman S, MacMillan JP, Cohen HJ. Effects of socioeconomic and clinical factors on survival in multiple myeloma. J Clin Oncol. 1987;5(12):1977–1984
  16. Cella DF, Orav EJ, Kornblith AB, et al. Socioeconomic status and cancer survival. J Clin Oncol. 1991;9(8):1500–1509
  17. Faggiano F, Partanen T, Kogevinas M, Boffetta P. Socioeconomic differences in cancer incidence and mortality. IARC Sci Publ. 1997;138:65–176
  18. Alcalai R, Ben-Yehuda D, Ronen I, Paltiel O. Ethnicity and prognosis in acute myeloid leukemia. Am J Hematol. 2003;72(2):127–134
  19. Oh H, Loberiza FR, Zhang MJ, et al. Comparison of graft-versus-host-disease and survival after HLA-identical sibling bone marrow transplantation in ethnic populations. Blood. 2005;105(4):1408–1416
  20. Baker KS, Loberiza FR, Yu H, et al. Outcome of ethnic minorities with acute or chronic leukemia treated with hematopoietic stem-cell transplantation in the United States. J Clin Oncol. 2005;23(28):7032–7042
  21. Cancer Stat Fact Sheets: Myeloma. Available from: http://seer.cancer.gov/statfacts/html/nhl.html?statfactspage=nhl.html&x=13&y=14. Accessed March 12, 2006.
  22. Petralia SA, Dosemeci M, Adams EE, Zahm SH. Cancer mortality among women employed in health care occupations in 24 U.S. states, 1984-1993. Am J Ind Med. 1999;36(1):159–165
  23. Burnett C, Robinson C, Walker J. Cancer mortality in health and science technicians. Am J Ind Med. 1999;36(1):155–158
  24. Cocco P, Kazerouni N, Zahm SH. Cancer mortality and environmental exposure to DDE in the United States. Environ Health Perspect. 2000;108(1):1–4
  25. Friedman GD, Herrinton LJ. Obesity and multiple myeloma. Cancer Causes Control. 1994;5(5):479–483
  26. Brown LM, Gridley G, Pottern LM, et al. Diet and nutrition as risk factors for multiple myeloma among blacks and whites in the United States. Cancer Causes Control. 2001;12(2):117–125
  27. Brown LM, Pottern LM, Silverman DT, et al. Multiple myeloma among Blacks and Whites in the United States: role of cigarettes and alcoholic beverages. Cancer Causes Control. 1997;8(4):610–614
  28. Patel M, Mahlangu J, Patel J, et al. Kaposi sarcoma-associated herpesvirus/human herpesvirus 8 and multiple myeloma in South Africa. Diagn Mol Pathol. 2001;10(2):95–99
  29. Nossent JC, Winkel CN, van Leeuwen JC. Multiple myeloma in the Afro-Caribbean population of Curacao. Neth J Med. 1993;43(5-6):210–214
  30. Koessel SL, Theis MK, Vaughan TL, et al. Socioeconomic status and the incidence of multiple myeloma. Epidemiology. 1996;7(1):4–8
  31. Cohen HJ, Crawford J, Rao MK, Pieper CF, Currie MS. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med. 1998;104(5):439–444
  32. Bowden M, Crawford J, Cohen HJ, Noyama O. A comparative study of monoclonal gammopathies and immunoglobulin levels in Japanese and United States elderly. J Am Geriatr Soc. 1993;41(1):11–14
  33. Pottern LM, Gart JJ, Nam JM, et al. HLA and multiple myeloma among black and white men: evidence of a genetic association. Cancer Epidemiol Biomarkers Prev. 1992;1(3):177–182
  34. Leech SH, Bryan CF, Elston RC, Rainey J, Bickers JN, Pelias MZ. Genetic studies in multiple myeloma. 1 (Association with HLA-Cw5). Cancer. 1983;51(8):1408–1411
  35. Brown LM, Linet MS, Greenberg RS, et al. Multiple myeloma and family history of cancer among blacks and whites in the U.S.. Cancer. 1999;85(11):2385–2390
  36. Pottern LM, Heineman EF, Olsen JH, Raffn E, Blair A. Multiple myeloma among Danish women: employment history and workplace exposures. Cancer Causes Control. 1992;3(5):427–432
  37. Riedel DA, Pottern LM. The epidemiology of multiple myeloma. Hematol Oncol Clin North Am. 1992;6(2):225–247
  38. Baris D, Brown LM, Silverman DT, et al. Socioeconomic status and multiple myeloma among US blacks and whites. Am J Public Health. 2000;90(8):1277–1281
  39. McWhorter WP, Schatzkin AG, Horm JW, Brown CC. Contribution of socioeconomic status to black/white differences in cancer incidence. Cancer. 1989;63(5):982–987
  40. Lenhard RE, Enterline JP, Crowley J, Ho GY. The effects of distance from primary treatment centers on survival among patients with multiple myeloma. J Clin Oncol. 1987;5(10):1640–1645
  41. Sinha R, Lonial S. Novel treatment approaches for patients with relapsed and refractory multiple myeloma. Curr Treat Options Oncol. 2006;7(3):246–257
  42. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med. 2004;351(18):1860–1873
  43. Attal M, Harousseau JL, Stoppa AM, et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma (Intergroupe Francais du Myelome). N Engl J Med. 1996;335(2):91–97
  44. Anderson KC, Alsina M, Bensinger W, et al. NCCN: multiple myeloma (NCCN Clinical Practice Guidelines in Oncology). vol. 8. 2006;
  45. Hayes N, Rollins R, Weinberg A, et al. Cancer-related disparities: weathering the perfect storm through comprehensive cancer control approaches. Cancer Causes Control. 2005;16(suppl 1):41–50
  46. Bickell NA, Wang JJ, Oluwole S, et al. Missed opportunities: racial disparities in adjuvant breast cancer treatment. J Clin Oncol. 2006;24(9):1357–1362
  47. Groman R, Ginsburg J. Racial and ethnic disparities in health care: a position paper of the American College of Physicians. Ann Intern Med. 2004;141(3):226–232
  48. Modiano MR, Villar-Werstler P, Crowley J, Salmon SE. Evaluation of race as a prognostic factor in multiple myeloma (An ancillary of Southwest Oncology Group Study 8229). J Clin Oncol. 1996;14(3):974–977
  49. Saraf S, Chen YH, Dobogai LC, Mahmud N, Peace D, et al. Prolonged responses after autologous stem cell transplantation in African-American patients with multiple myeloma. Bone Marrow Transplant. 2006;37(12):1099–1102Epub 2006 May 8
  50. Mills PK, Yang RC, Riordan D. Cancer incidence in the Hmong in California, 1988-2000. Cancer. 2005;104(12):2969–2974(suppl)
  51. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS. Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood. 2006;107(1):265–276
  52. Morton LM, Engels EA, Holford TR, et al. Hepatitis C virus and risk of non-Hodgkin lymphoma: a population-based case-control study among Connecticut women. Cancer Epidemiol Biomarkers Prev. 2004;13(3):425–430
  53. Zhang Y, Holford TR, Leaderer B, et al. Hair-coloring product use and risk of non-Hodgkin’s lymphoma: a population-based case-control study in Connecticut. Am J Epidemiol. 2004;159(2):148–154
  54. Zhang Y, Holford TR, Leaderer B, et al. Menstrual and reproductive factors and risk of non-Hodgkin’s lymphoma among Connecticut women. Am J Epidemiol. 2004;160(8):766–773
  55. Zhang Y, Holford TR, Leaderer B, et al. Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control. 2004;15(4):419–428
  56. Zheng T, Holford TR, Leaderer B, et al. Diet and nutrient intakes and risk of non-Hodgkin’s lymphoma in Connecticut women. Am J Epidemiol. 2004;159(5):454–466
  57. Chang ET, Smedby KE, Zhang SM, et al. Alcohol intake and risk of non-Hodgkin lymphoma in men and women. Cancer Causes Control. 2004;15(10):1067–1076
  58. Briggs NC, Levine RS, Hall HI, Cosby O, Brann EA, Hennekens CH. Occupational risk factors for selected cancers among African American and White men in the United States. Am J Public Health. 2003;93(10):1748–1752
  59. Brown ML, Riley GF, Schussler N, Etzioni R. Estimating health care costs related to cancer treatment from SEER-Medicare data. Med Care. 2002;40(8):IV104–IV117(suppl)
  60. Jaffe ES, Harris NL, Stein H, Vardiman V. World Health Organization Classification of Tumours.: Pathology and Genetics of Tumours of Hematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2001;
  61. Feugier P, Van Hoof A, Sebban C, et al. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d’Etude des Lymphomes de l’Adulte. J Clin Oncol. 2005;23(18):4117–4126
  62. Fisher RI, LeBlanc M, Press OW, Maloney DG, Unger JM, Miller TP. New treatment options have changed the survival of patients with follicular lymphoma. J Clin Oncol. 2005;23(33):8447–8452
  63. Savage KJ, Monti S, Kutok JL, et al. The molecular signature of mediastinal large B-cell lymphoma differs from that of other diffuse large B-cell lymphomas and shares features with classical Hodgkin lymphoma. Blood. 2003;102(12):3871–3879
  64. Shipp MA, Ross KN, Tamayo P, et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning. Nat Med. 2002;8(1):68–74
  65. Cancer Stat Fact Sheets: Lymphoma. Available from: http://seer.cancer.gov/statfacts/html/nhl.html?statfactspage=nhl.html&x=13&y=14. Accessed March 12, 2006.
  66. Fisher RI, Miller TP, O’Connor OA. Diffuse aggressive lymphoma. Hematology (Am Soc Hematol Educ Program). 2004;221–236
  67. Miller TP, Dahlberg S, Cassady JR, et al. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N Engl J Med. 1998;339(1):21–26
  68. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med. 2002;346(4):235–242
  69. Pfreundschuh MG, Trumper L, Ma D, et al. Randomized intergroup trial of first line treatment for patients ≤60 years with diffuse large B-cell non-Hodgkin’s lymphoma (DLBCL) with a CHOP-like regimen with or without the anti-CD20 antibody rituximab: early stopping after the first interim analysis. Proc Amer Soc Clin Oncol. 2004;Abstract #6500
  70. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol. 2005;23(22):5027–5033
  71. Hornberger JC, Best JH. Cost utility in the United States of rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone for the treatment of elderly patients with diffuse large B-cell lymphoma. Cancer. 2005;103(8):1644–1651
  72. State Cancer Profiles: Non-Hodgkin Lymphoma. Available from: http://statecancerprofiles.cancer.gov/cgi-bin/quickprofiles/profile.pl?13&086. Accessed March 12, 2006.
  73. Powe NR, Cooper LA. Diversifying the racial and ethnic composition of the physician workforce. Ann Intern Med. 2004;141(3):223–224
  74. Lavizzo-Mourey R, Lumpkin JR. From unequal treatment to quality care. Ann Intern Med. 2004;141(3):221
  75. Kaplan SH, Greenfield S. The Patient’s role in reducing disparities. Ann Intern Med. 2004;141(3):222–223
  76. Reddy S, Shapiro M, Morton R, Brawley OW. Prostate cancer in black and white Americans. Cancer Metastasis Rev. 2003;22(1):83–86
  77. Cooper LA, Hill MN, Powe NR. Designing and evaluating interventions to eliminate racial and ethnic disparities in health care. J Gen Intern Med. 2002;17(6):477–486
  78. Caplan LS, Helzlsouer KJ, Shapiro S, Freedman LS, Coates RJ, Edwards BK. System delay in breast cancer in whites and blacks. Am J Epidemiol. 1995;142(8):804–812
  79. Flum DR, Stuart S, Wilcox M. Processes and outcomes of care among navajo women with breast cancer. J Am Med Assoc. 2003;290(15):1996–1997
  80. Richards MA, Smith P, Ramirez AJ, Fentiman IS, Rubens RD. The influence on survival of delay in the presentation and treatment of symptomatic breast cancer. Br J Cancer. 1999;79(5-6):858–864
  81. Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. Lancet. 1999;353(9159):1119–1126
  82. Switzer GE, Dew MA, Harrington DJ, et al. Ethnic differences in donation-related characteristics among potential hematopoietic stem cell donors. Transplantation. 2005;80(7):890–896
  83. Rosen AB, Tsai JS, Downs SM. Variations in risk attitude across race, gender, and education. Med Decis Making. 2003;23(6):511–517
  84. Cykert S, Phifer N. Surgical decisions for early stage, non-small cell lung cancer: which racially sensitive perceptions of cancer are likely to explain racial variation in surgery?. Med Decis Making. 2003;23(2):167–176
  85. Greiner KA, Born W, Nollen N, Ahluwalia JS. Knowledge and perceptions of colorectal cancer screening among urban African Americans. J Gen Intern Med. 2005;20(11):977–983
  86. Lara PN, Paterniti DA, Chiechi C, et al. Evaluation of factors affecting awareness of and willingness to participate in cancer clinical trials. J Clin Oncol. 2005;23(36):9282–9289
  87. Trauth JM, Jernigan JC, Siminoff LA, Musa D, Neal-Ferguson D, Weissfeld J. Factors affecting older african american women’s decisions to join the PLCO Cancer Screening Trial. J Clin Oncol. 2005;23(34):8730–8738
  88. Taylor V, Lessler D, Mertens K, et al. Colorectal cancer screening among African Americans: the importance of physician recommendation. J Natl Med Assoc. 2003;95(9):806–812
  89. Sellers DB, Ross LE. African American men, prostate cancer screening and informed decision making. J Natl Med Assoc. 2003;95(7):618–625
  90. Cacioppo JT, Petty RE, Kao CF. The efficient assessment of need for cognition. J Personality Assess. 1984;48(3):306
  91. Simon AF, Fagley NS, Halleran JG. Decision framing: moderating effects of individual differences and cognitive processing. J Behav Decis Making. 2004;17(2):77–93
  92. Williams-Piehota P, Pizarro J, Schneider TR, Mowad L, Salovey P. Matching health messages to monitor-blunter coping styles to motivate screening mammography. Health Psychol. 2005;24(1):58–67
  93. Webster DM, Kruglanski AW. Individual differences in need for cognitive closure. J Personality Social Psychol. 1994;67(6):1049–1062
  94. Johnson MF, Lin M, Mangalik S, Murphy DJ, Kramer AM. Patients’ perceptions of physicians’ recommunication for comfort care differ by patient age and gender. J Gen Intern Med. 2000;15(4):248–255
  95. Llewellyn-Thomas HA, McGreal MJ, Thiel EC. Cancer patients’ decision making and trial-entry preferences: the effects of “framing” information about short-term toxicity and long-term survival. Med Decis Making. 1995;15(1):4–12
  96. Froberg DG, Kane RL. Methodology for measuring health-state preferences (I. Measurement strategies). J Clin Epidemiol. 1989;42(4):345–354
  97. Frosch DL, Kaplan RM. Shared decision making in clinical medicine: past research and future directions. Am J Prev Med. 1999;17(4):285–294

 This research was funded a research startup award from the Winship Cancer Institute at Emory University and the Georgia Cancer Coalition Distinguished Clinician and Scientists Award.

PII: S0147-0272(07)00006-2

doi: 10.1016/j.currproblcancer.2007.01.005

Current Problems in Cancer
Volume 31, Issue 3 , Pages 182-201 , May 2007

Article Tools

* Image Usage & Resolution